發(fā)布時(shí)間：2018-04-01 15:33

  本文選題：紫杉醇　切入點(diǎn)：洛鉑　出處：《中國(guó)藥房》2017年17期

【摘要】：目的:探討紫杉醇聯(lián)合洛鉑經(jīng)介入栓塞給藥對(duì)宮頸癌患者的化療療效和安全性。方法:選取我院2010年5月-2014年3月收治的宮頸癌患者68例,按照治療方案分為對(duì)照組和觀察組,各34例。對(duì)照組患者給予注射用紫杉醇脂質(zhì)體175 mg/m2加至5%葡萄糖注射液250 m L,ivgtt+注射用洛鉑80 mg/m2加至5%葡萄糖注射液250 mL,ivgtt;觀察組患者采用動(dòng)脈穿刺插管經(jīng)動(dòng)脈造影選取子宮動(dòng)脈和腫瘤血管,以明膠海綿栓塞,同時(shí)經(jīng)穿刺導(dǎo)管注入注射用紫杉醇脂質(zhì)體175 mg/m~2+注射用洛鉑80 mg/m2+5%葡萄糖注射液10 m L。兩組患者均在每個(gè)療程第1天給藥,以21 d為1個(gè)療程,共治療3個(gè)療程。觀察兩組患者臨床療效、治療前后T淋巴細(xì)胞亞群(CD4~+、CD8~+、CD4~+/CD8~+)水平;記錄治療過(guò)程中不良反應(yīng)發(fā)生情況、治療2年后的局部復(fù)發(fā)與轉(zhuǎn)移情況,以及生存情況。結(jié)果:觀察組患者治療總有效率(85.29%)明顯高于對(duì)照組(61.76%),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療前,兩組患者CD4~+、CD8~+和CD4~+/CD8~+水平比較,差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05);治療后,兩組患者CD4~+和CD4~+/CD8~+水平均明顯升高,CD8~+水平明顯降低,且觀察組患者上述水平改善較對(duì)照組明顯,差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。觀察組患者生存時(shí)間[(22.58±0.61)個(gè)月]明顯長(zhǎng)于對(duì)照組[(17.61±1.32)月],2年生存率(70.59%)明顯高于對(duì)照組(47.06%),差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。兩組患者的疾病控制率、總不良反應(yīng)發(fā)生率、局部復(fù)發(fā)與轉(zhuǎn)移率比較,差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:紫杉醇聯(lián)合洛鉑經(jīng)介入栓塞給藥對(duì)宮頸癌患者的化療療效明確,可改善其T淋巴細(xì)胞亞群水平,且安全性較高。
[Abstract]:Objective: to investigate the efficacy and safety of paclitaxel combined with loplatin embolization in the treatment of cervical cancer. Methods: 68 patients with cervical cancer admitted in our hospital from May 2010 to March 2014 were divided into control group and observation group according to the treatment plan. 34 patients in each group were treated with paclitaxel liposome 175 mg/m2 plus 5% glucose injection 250m / L iv GTT for injection of roplatin 80 mg/m2 plus 5% glucose injection 250ml iv gtt, and patients in the observation group were treated with arterial puncture intubation via arteriography. Select uterine arteries and tumor blood vessels, After embolization with gelatin sponge and injection of paclitaxel liposome 175 mg/m~2 through puncture catheter, 10 mL / L loplatin 80 mg/m2 5% glucose injection was used for injection. The patients in both groups were given the drug on the first day of each course of treatment, 21 days as a course of treatment. Three courses of treatment were used to observe the clinical efficacy of the two groups, the level of CD4 ~ + CD8 ~ / CD4 ~ / CD8 ~) of T lymphocyte subsets before and after treatment, and to record the occurrence of adverse reactions and the local recurrence and metastasis after 2 years of treatment. Results: the total effective rate of treatment in the observation group was significantly higher than that in the control group (61.76), and the difference was statistically significant (P 0.05). Before treatment, there was no significant difference between the two groups in the levels of CD4 ~ + CD8 ~ and CD4- / -CD8 ~ ~; after treatment, there was no significant difference between the two groups. The levels of CD4 ~ and CD4 ~ / / CD8~ in the two groups were significantly increased and decreased, and the improvement of the above levels in the observation group was more obvious than that in the control group. The survival time of patients in the observation group [22.58 鹵0.61months] was significantly longer than that in the control group [17.61 鹵1.32months], and the 2-year survival rate was 70.59m higher than that in the control group (47.065.The difference was statistically significant (P 0.05). The disease control rate and the total adverse reaction rate of the two groups were significantly higher than those in the control group. There was no significant difference between local recurrence and metastasis rates (P 0.05). Conclusion: the chemotherapeutic efficacy of paclitaxel combined with loplatin through interventional embolization for cervical cancer patients is clear, and it can improve the level of T lymphocyte subsets in patients with cervical cancer.
【作者單位】： 崇州市婦幼保健院婦科;
【基金】：四川省衛(wèi)生和計(jì)劃生育委員會(huì)科研課題(No.150049)
【分類號(hào)】：R737.33

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 馬瑛,張勇,李碧珍,唐華,王鴻志;放射性介入栓塞法在剖宮產(chǎn)術(shù)后晚期子宮出血的應(yīng)用[J];實(shí)用婦產(chǎn)科雜志;2000年03期

2 梁煒;;介入栓塞治療難治性產(chǎn)后大出血的觀察與護(hù)理[J];臨床護(hù)理雜志;2009年06期

3 孫曉龍;石紅春;;介入栓塞治療產(chǎn)后大出血33例報(bào)道[J];重慶醫(yī)學(xué);2011年10期

4 楊弋弋;;產(chǎn)后大出血的介入栓塞治療[J];醫(yī)學(xué)理論與實(shí)踐;2006年04期

5 張莉;;介入栓塞子宮動(dòng)脈治療產(chǎn)后大出血58例臨床分析[J];中國(guó)醫(yī)藥指南;2012年09期

6 王靜;斯光晏;;介入栓塞治療婦產(chǎn)科急性大出血的臨床效果[J];現(xiàn)代診斷與治療;2014年04期

7 張勇,茅一斌;動(dòng)脈介入栓塞治療產(chǎn)后大出血5例[J];現(xiàn)代中西醫(yī)結(jié)合雜志;2005年17期

8 淡緒國(guó);;介入栓塞治療產(chǎn)后大出血臨床觀察[J];中國(guó)實(shí)用醫(yī)藥;2014年21期

9 曾憲強(qiáng);李義;丁小琳;王榮勤;邵合德;;急診介入栓塞治療產(chǎn)后大出血[J];醫(yī)藥論壇雜志;2006年16期

10 朱愛(ài)華;龔輝;;介入栓塞治療難治性產(chǎn)后大出血20例臨床分析[J];交通醫(yī)學(xué);2011年01期

相關(guān)會(huì)議論文 前2條

1 孫立軍;;腹、盆部出血診斷和介入栓塞治療[A];中華醫(yī)學(xué)會(huì)第十三屆全國(guó)放射學(xué)大會(huì)論文匯編（上冊(cè)）[C];2006年

2 王鶴鵬;武長(zhǎng)軍;;子宮肌瘤介入栓塞治療的臨床觀察[A];河南省第二屆腫瘤微創(chuàng)治療學(xué)術(shù)大會(huì)暨新鄉(xiāng)抗癌協(xié)會(huì)腫瘤微創(chuàng)治療專業(yè)委員會(huì)成立大會(huì)、河南省胸部疾病影像診斷與治療新進(jìn)展研討會(huì)暨新鄉(xiāng)市影像診斷新進(jìn)展與新技術(shù)研討會(huì)論文匯編[C];2007年

相關(guān)碩士學(xué)位論文 前2條

1 謝n，

本文編號(hào)：1696153